Lyophilisation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-21. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
| Property | Value | Notes |
|---|---|---|
| Solid-state storage | -20 degrees Celsius or lower | Desiccated and protected from light |
| Solution stability | Short and method-dependent | Confirm by stability testing |
| Purity assessment | Reversed-phase HPLC | Reported as area percent |
| Identity confirmation | LC-MS or comparable method | Mass match against expected value |
| Common synonyms | MT-II; melanotan II | Informal and catalogue names |
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
=== Step-growth polymerization === Step-growth polymerization involves two monomers with bi- or multifunctionality to form polymer chains. Many polymers are synthesized via step-growth polymerization and include polyesters, polyamides, and polyurethanes. A sub-class of step-growth polymerization is condensation polymerization.
=== Exposure-response === Exposure-Response models establish the relationship between drug exposure and clinical response. They play a crucial role in determining the optimal therapeutic range and predicting the likelihood of efficacy or adverse events. These models not only guide dose individualization based on desired clinical outcomes but also provide information on population exposure-response relationships for effects and adverse effects.
== Production == The major producers of strontium as celestine as of January 2024 are Spain (200,000 t), Iran (200,000 t), China (80,000 t), Mexico (35,000 t); and Argentina (700 t). Although strontium deposits occur widely in the United States, they have not been mined since 1959. A large proportion of mined celestine is converted to the carbonate by two processes. Either the celestine is directly leached with sodium carbonate solution or the celestine is roasted with coal to form the sulfide. The second stage produces a dark-coloured material containing mostly strontium sulfide. This so-called "black ash" is dissolved in water and filtered. Strontium carbonate is precipitated from the strontium sulfide solution by introduction of carbon dioxide. The sulfate is reduced to the sulfide by the carbothermic reduction:
Pre-formed mediators stored in granules biogenic amines (histamine, serotonin, dopamine) proteases (serine proteases including tryptase and chymase, aspartic acid proteases, cysteine proteases, metalloproteinases including CPA3) proteoglycans (heparin, chondroitin sulfate) cytokines (TNF, IL-4) growth factors (GM-CSF, bFGF, VEGF, NGF) lysosomal enzymes (β-hexosaminidase, β-glucuronidase, CD63) Newly synthesized inflammatory mediators lipid mediators (eicosanoids, thromboxane, LTB4, LTC4, PAF, PGD2) neuropeptides (CRH, VIP) growth factors (PDGF, GnRH) chemokines (MCP-1, eotaxin, TARC, RANTES) cytokines (IL-1, IL-3, IL-6, IL-18, SCF, TGF-β)
=== Chemistry === Capensinidin (Cp), a blue-red plant dye Carbon monophosphide, a diatomic radical chemical compound Cassiopium (Cp), a name formerly used for the chemical element Lutetium Chlorinated paraffins (CPs), complex mixtures of polychlorinated n-alkanes Copernicium, a chemical element, with proposed symbol Cp Counterpoise method, a way to correct for basis set superposition error in quantum chemistry Cross-polarization Cyclopentadienyl complex (Cp), read as "C P", the cyclic C5H5 fragment in a coordination complex The similar symbol Cp* ("C P star") represents pentamethylcyclopentadienyl, the C5Me5 ligand
Sources: en.wikipedia.org
=== Other === The Congress that passed the Taft–Hartley Amendments considered repealing the Norris–La Guardia Act to the extent necessary to permit courts to issue injunctions against strikes violating a no-strike clause, but chose not to do so. The Supreme Court nonetheless held several decades later that the act implicitly gave the courts the power to enjoin such strikes over subjects that would be subject to final and binding arbitration under a collective bargaining agreement. Finally, the act imposed a number of procedural and substantive standards that unions and employers must meet before they may use employer funds to provide pensions and other employee benefit to unionized employees. Congress has since passed more extensive protections for workers and employee benefit plans as part of the Employee Retirement Income Security Act ("ERISA").
=== Dietary intake === The Dietary Reference Intake (DRI) Recommended Daily Amount (RDA) for vitamin A for a 25-year-old male is 900 micrograms/day, or 3000 IU. National Health Service daily recommended values are slightly lower at 700 micrograms for men and 600 micrograms for women. During the absorption process in the intestines, retinol is incorporated into chylomicrons as the ester form, and it is these particles that mediate transport to the liver. Liver cells store vitamin A as the ester, and when retinol is needed in other tissues, it is de-esterifed and released into the blood as the alcohol. Retinol then attaches to a serum carrier, retinol binding protein, for transport to target tissues. A binding protein inside cells, cellular retinoic acid binding protein, serves to store and move retinoic acid intracellularly.
Competence stimulating peptides (CSP) are chemical messengers that assist the initiation of quorum sensing, and exist in many bacterial genera. Bacterial transformation of DNA is driven by CSP-coupled quorum sensing.
Abrasion Acrocyanosis Actinic prurigo (familial polymorphous light eruption of American Indians, hereditary polymorphous light eruption of American Indians, Hutchinson's summer prurigo, hydroa aestivale) Aerosol burn Benign summer light eruption Beryllium granuloma Black heel and palm (black heel, calcaneal petechiae, chromidrose plantaire, post-traumatic punctate intraepidermal hemorrhage, tache noir) Callus (callosity, clavus, corn, heloma, heloma durum, heloma molle, intractable plantar keratosis, tyloma) Carbon stain Chilblains (pernio, perniosis) Chronic actinic dermatitis (actinic reticuloid, chronic photosensitivity dermatitis, persistent light reactivity, photosensitive eczema) Colloid milium Coma blister Delayed blister Dermatosis neglecta Edema blister (edema bulla, hydrostatic bulla, stasis blister) Electrical burn Equestrian perniosis Erythema ab igne (fire stains, toasted skin syndrome) Erythrocyanosis crurum Favre–Racouchot syndrome (Favre–Racouchot disease, nodular cutaneous elastosis with cysts and comedones) Foreign body reaction Fracture blister Friction blister Frostbite Garrod's pad (violinist's pad) Harpist's finger Heel stick wound Heat edema Hot tar burn Hunan hand syndrome (chili burn) Hydroa vacciniforme (Bazin's hydroa vacciniforme) Jogger's nipple Juvenile spring eruption Kairo cancer Kang cancer Kangri ulcer Lightning burn Loop mark Magnetic resonance imaging burn (MRI burn) Mercury granuloma Miliaria crystallina (miliaria crystalline, sudamina) Miliaria profunda (mammillaria) Miliaria pustulosa Miliaria rubra (heat rash, prickly heat) Narcotic dermopathy Occlusion miliaria Painful fat herniation (painful piezogenic pedal papules, piezogenic papules) Peat fire cancer Photoaging (dermatoheliosis) Photosensitivity with HIV infection Phototoxic tar dermatitis Photosenitization Phytophotodermatitis (Berloque dermatitis) Pinch mark Polymorphous light eruption (polymorphic light eruption) Postmiliarial hypohidrosis Postoperative hematoma Pressure ulcer (decubitus ulcer) Pseudoacanthosis nigricans Pseudoverrucous papules and nodules Pulling boat hands PUVA-induced acrobullous dermatosis Runner's rump Sclerosing lymphangiitis Silica granuloma Silicone granuloma Skin pop scar Skin track Slap mark Solar erythema Soot tattoo Subcutaneous emphysema Sucking blister Sunburn Hell's itch Surfer's knots Talon noir Tattoo Tennis toe Thermal burn Traumatic asphyxia Trench foot Tropical anhidrotic asthenia Tropical immersion foot (paddy foot, paddy-field foot) Turf toe Uranium dermatosis UV-sensitive syndrome Vibration white finger (dead finger, hand–arm vibration syndrome) Warm water immersion foot Weathering nodule of ear Wrestler's ear (cauliflower ear, traumatic auricular hematoma) Zirconium granuloma
According to the study, however, when estimating the length of their partner's penis, most women would say a size significantly smaller than what their partner was recorded to be. This suggests that perception of size is not entirely accurate. The visual impression of the size is not necessarily in correlation with the feeling in the vulva and vagina. A very long penis can cause dyspareunia, if the man does not understand how to use it carefully.
Sources: en.wikipedia.org
=== Officers === To gain a commission, Potential Officers have to pass the two stages of the Army Officer Selection Board (AOSB) and then successfully complete four modules of training, which together form the Army Reserve Commissioning Course. For professionally qualified officers (doctors, vets, lawyers etc.), there is only one stage at the AOSB. Module A consists of basic field training and elementary military skills. This can be completed at either a UOTC over a number of weekends or over 2 weeks at the Royal Military Academy Sandhurst (RMAS). Module B covers training in Tactics, Leadership, Doctrine and Navigation, both in theory and in practice, with a focus on the section battle drills and the platoon combat estimate. This training can either be spread over 10 weekends at a UOTC, or 2 weeks at the RMAS. Module C builds on the Tactics, Leadership, Doctrine, and Navigation taught in Module B, with a greater focus on the theory behind these constructs. CBRN training is also added at this point, and Officer Cadets undergo a number of field exercises to test their military and leadership skills. Module C can only be undertaken at the RMAS. Module D Once the Officer Cadet has completed their Army Officer Selection Board, they can complete this final module, after which they will become commissioned officers in the British Army. Based at the RMAS, this module consists primarily of a prolonged field exercise, followed by drill training in preparation for the passing out parade.
=== CPT-II deficiency === Carnitine palmitoyltransferase II deficiency (also known as CPT-II deficiency) leads to an excess long chain fatty acids, as the body lacks the ability to transport fatty acids into the mitochondria to be processed as a fuel source. The disease is caused by a defect in the gene CPT2. This deficiency will present in patients in one of three ways: lethal neonatal, severe infantile hepatocardiomuscular, and myopathic form. The myopathic is the least severe form of the deficiency and can manifest at any point in the lifespan of the patient. The other two forms appear in infancy. Common symptoms of the lethal neonatal form and the severe infantile forms are liver failure, heart problems, seizures and death. The myopathic form is characterized by muscle pain and weakness following vigorous exercise. Treatment generally includes dietary modifications and carnitine supplements.
The failure to order a full evacuation of the South Tower after the first plane crash into the North Tower was described by USA Today as "one of the day's great tragedies." As exemplified in the photograph The Falling Man, more than 200 people fell to their deaths from the burning towers, most of whom were forced to jump to escape the extreme heat, fire and smoke. Some occupants of each tower above the point of impact made their way toward the roof in the hope of helicopter rescue, but the roof access doors were locked. No plan existed for helicopter rescues, and the combination of roof equipment, thick smoke and intense heat prevented helicopters from approaching. At the World Trade Center complex, 414 emergency workers died as they tried to rescue people and fight fires. Another law enforcement officer was killed when United 93 crashed. 343 firefighters of the New York City Fire Department (FDNY) died, including a chaplain and two paramedics. 23 officers of New York City Police Department (NYPD) died. 37 officers of the Port Authority Police Department (PAPD) died. Eight emergency medical technicians and paramedics from private emergency medical services units were killed. Almost all of the emergency personnel who died at the scene were killed as a result of the towers collapsing, with the exception of one who was struck by a civilian falling from the South Tower. 658 employees from Cantor Fitzgerald L.P., an investment bank on the North Tower's 101st–105th floors, died, considerably more than any other employer.
=== Disulfide bond cleavage === ECD itself and combined with other MS is very useful for proteins and peptides containing multiple disulfide bonds. FTICR combined with ECD helps to recognize peptides containing disulfide bonds. ECD could also access important sequence information by activation of higher charged proteins. Moreover, disulfide bond cleavage takes place by ECD of multiply charge proteins or peptides produced by ESI. Electron capture by these proteins releases H atom, captured by the disulfide bond to cause its dissociation.
Sources: en.wikipedia.org
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.
There is no single harmonised standard governing these products, and manufacturing conditions differ. Impurities may include truncated sequences, oxidation products, residual solvents, and counter-ions. Independent testing is often the only way to characterise a given lot.
Reported studies have looked at pigmentation, photoprotection, and metabolic or appetite-related endpoints in small experimental settings. Much of the evidence base is early-stage and limited in size. Questions about long-term effects and clinical relevance remain open.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.